Research Paper

Distinct roles of cortical and pallidal $\beta$ and $\gamma$ frequencies in hemiparkinsonian and dyskinetic rats

Agnese Salvadèa, Vincenza D’Angelo, Giuseppe Di Giovanni, Gerd Tinkhauser, Giuseppe Sancesario, Claudio Städler, Jens C. Möller, Alessandro Stefani, Alain Kaelin-Lang, Salvatore Galati

A Laboratory for Biomedical Neuroscience (LBN), Neurocenter of Southern Switzerland, Lugano, Switzerland
B Department of Neurology, University of Rome
C Department of Physiology and Biochemistry, University of Malta, Malta
D Department of Neurology, University of Bern, Switzerland
E Parkinson Center, Center for Neurological Rehabilitation, Zürich, Switzerland
F I.R.C.C.S. Fondazione S. Lucia, Rome, Italy

ARTICLE INFO

Article history:
Received 24 April 2015
Received in revised form 21 September 2015
Accepted 10 November 2015
Available online 10 November 2015

Keywords:
Beta band oscillation
Parkinson’s disease
Rat animal model
Local field potentials
Recordings in freely moving animals

ABSTRACT

Enhanced $\beta$ band ($\beta$B) activity, which is suppressed by levodopa (LD) treatment, has been demonstrated within the basal ganglia (BG) of Parkinson’s disease (PD) patients. However, some data suggest that Parkinsonian symptoms are not directly related to this brain frequency and therefore, its causative role remains questionable. A less explored phenomenon is the link between the $\gamma$ band ($\gamma$B) and PD phenomenology. Here, we monitored the development of the oscillatory activity during chronic LD depletion and LD treatment in Parkinsonian and levodopa-induced dyskinesia (LID) in rats. We found a significant and bilateral power increase in the high $\beta$B frequencies (20–30 Hz) within the first 10 days after 6-hydroxydopamine (6-OHDA) lesion, which was in accordance with a significant depletion of dopaminergic fibers in the striatum. We also observed a clear-cut $\gamma$B increase during LD treatment. The development of LID was characterized by a slight increase in the cumulative power of $\beta$B accompanied by a large augmentation in the $\gamma$B frequency (60–80 Hz). This latter effect reached a plateau in the frontal cortex bilaterally and the left globus pallidus after the second week of LD treatment. Our data suggest that the $\beta$B parallels the emergence of Parkinsonian signs and can be taken as a predictive sign of DA depletion, matching TH-staining reduction. On the other hand, the $\gamma$B is strictly correlated to the development of LID. LD treatment had an opposite effect on $\beta$B and $\gamma$B, respectively.

1. Introduction

Loss of dopaminergic innervation of the striatum leads to excessive synchronized oscillatory firing within the basal ganglia (BG) circuitry. This oscillatory behavior occurs mainly in the beta band ($\beta$B) frequency, and it has been reported in both Parkinson’s disease (PD) patients and PD animal models (Steigerwald et al., 2008; Eusebio and Brown, 2006). The relation between $\beta$B oscillation and Parkinsonian symptoms has been identified in the cortex and BG of PD patients by local field potential (LFP) recordings. Further evidence from Parkinsonian animal models shows that these frequencies are clearly detected in the cortex during the transition from slow wave to a desynchronized pattern activity (Sharott et al., 2005; Mallet et al., 2008). Moreover, LFP recordings from PD patients without medication revealed prominent oscillations between 8 Hz and 30 Hz, which were suggested to be the BG $\beta$B and have resulted to be broader than the conventional $\beta$ electroencephalographic activity (Brown, 2006). The $\beta$B may be divided in two sub-ranges of frequencies, namely low $\beta$B (~10–20 Hz) and high $\beta$B (~20–30 Hz) with presumed different functional implications (Priori et al., 2004; Avila et al., 2010). Gamma band ($\gamma$B) also plays a key role in movement execution with an opposite functional significance to that of the $\beta$B. $\gamma$B is classically in a range of between 35 and 90 Hz (Engel and Fries, 2010), and it has become known as prokinetic oscillation, as it is implicated in the initiation of movement (Brown, 2003). In contrast, $\beta$B occurs in the maintenance of the current state. Furthermore, $\gamma$B was recently negatively correlated to bradykinesia (Sharott et al., 2014), corroborating the previously described positive correlation between $\gamma$B and improvement following dopaminergic treatment (Litvak et al., 2012).

Moreover, a direct causative relation between $\beta$B and PD has been inferred by the subtle clinical worsening of akinesia obtained by stimulating the sub-thalamic nucleus (STN) with the $\beta$B frequency (Timmermann et al., 2004; Eusebio et al., 2007). Nevertheless, a study performed in monkeys chronically intoxicated with 1-methyl 4-phenyl 1,2,3,6-Tetrahydropyridine (MPTP) showed that the appearance...
of Parkinsonian symptoms is not dependent on $\beta$B oscillation (Leblois et al., 2007). In agreement, results from a computational model demonstrated that moderate dopamine (DA) depletion is sufficient to provoke Parkinsonism, but only a severe DA reduction leads to the emergence of $\beta$B frequencies (Leblois et al., 2007). The dissociation between $\beta$B and clinical symptoms is also evident in studies performed on PD patients where it is not correlated with clear changes in motor performance, rather, it is correlated to clinical amelioration after LD challenge (Weinberger et al., 2006). Of note, $\beta$B recorded in STN of PD patients correlated with limb rigidity, but there was no clear association with the main symptom of Parkinson syndrome, i.e., the bradykinesia (Sharott et al., 2014). Surprisingly, bradykinesia was inversely correlated with the neuronal oscillation in the $\gamma$B range (Sharott et al., 2014). While pharmacological STN inhibition is able to give clinical benefit without suppressing $\beta$B (Levy et al., 2001), $\beta$ power recorded within the STN is suppressed prior to movement initiation with a clear correlation with task demands. Furthermore, recent investigations performed in PD patients subjected to functional surgery have revealed a new perspective on the fine balance between $\beta$ and $\gamma$ oscillations during a simple stop signal task (Alegre et al., 2013).

Based on these results, the aim of the present study was to monitor these two bands in the frontal cortex and the globus pallidus (GP) in 6-hydroxydopamine (6-OHDA)-Parkinsonian freely moving rats. We focused our study on the GP because in a normal condition inversely-related to the STN, its activity is relatively unaffected by the cortical activity (Galati et al., 2009). Moreover, the dynamic changes of $\beta$B and $\gamma$B were correlated to behavioral modification in Parkinsonian rat motor performance and, furthermore, to the development of LD-induced dyskinesia (LID).

2. Methods

2.1. Animals at LBN: experimental design

24 adult male Sprague–Dawley rats (Harlan Italy, Udine), weighing 170–200 g at the beginning of experiment, were randomly housed in the animal rooms at LBN. They were placed under a 24-h cycle consisting of 12 h of light and 12 h of darkness with free access to food and water. The room temperature, humidity, and air exchange were automatically controlled. All animal procedures were approved by the Animal Research Committee and the Veterinary Office of the Canton of Ticino, Switzerland. Twenty-three rats received a unilateral DA-denervating lesion by stereotactic injection of 6-OHDA toxin into the left medial forebrain bundle, as described below. One rat received a sham surgery lesion. During the same surgical procedure rats were also implanted with electrodes for electrophysiological recordings. Five 6-OHDA-lesioned rats presented technical problems (bad quality of LFP recordings or electrode removal) and were thus excluded. Seventeen rats were successfully lesioned (Apo test positive), whereas, one rat did not display unilateral dopaminergic lesion (Apo test negative) and was excluded from data analysis. Five 6-OHDA-lesioned rats were sacrificed after the APO test, whereas, 11 rats followed the study with LD treatment and 1 rat followed the study without LD. 4 weeks after APO test, 8 rats (6-OHDA-lesioned and LD treated) were selected for LD test. The study design and the number of animals are depicted in Fig. 1A.

2.2. Animals at the Department of Neurology, University of Rome

Additional histological experiments were conducted in the laboratory of University of Rome Tor Vergata in compliance with Italian laws on animal experimentation (D.L. 116/1992) and with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. This sub-set of experiments was carried out on additional 12 adult male rats, weighing 250–300 g, plus 7 out of 24 rats treated at the LBN.

2.3. Unilateral 6-OHDA lesion model of PD

Unilateral (left hemisphere) DA denervation was performed according to a standard protocol (Schwarting and Huston, 1996; Galati et al., 2008). Briefly, rats were anesthetized with 1.5–2.5% isoflurane in oxygen and mounted on a stereotactic instrument (Stoelting Co., Wheat Lane, Wood Dale, IL, USA). Body temperature was maintained at 37°C–38°C with a heating pad (Stoelting Co., Wheat Lane, Wood Dale, IL, USA) placed beneath the animal. After a sub-cutaneous injection of the local anesthetic lidocaine, a midline scalp incision was made and a hole (0–1.0 mm) was drilled in the skull on the left side. The neurotoxin (30 mM solution of 6-OHDA containing 0.03% of ascorbic acid) was injected through the medial forebrain bundle (MF; coordinates: 4.0 mm posterior of the bregma, 1.3 mm laterally of the midline and 7.0 mm beneath the cortical surface). Injections of 3 μl of 6-OHDA were administered through a 30-gauge cannula connected to a 10 μl Hamilton syringe over a period of 3 min. The injection of the neurotoxin was preceded by a bolus of desipramine (25 mg/kg, i.p.) in order to minimize the uptake of 6-OHDA by noradrenergic neurons. After the 6-OHDA lesion, during the same surgical procedures, electrodes for electrophysiological recordings were implanted (see in Methods, sub-section Electrophysiological recordings).

Twenty days later, an apomorphine (APO)-induced rotation test (0.05 mg/kg, s.c.) was performed in order to assess the severity of nigral lesions (Galati et al., 2008; Hudson et al., 1993). Animals performing at least 100 rotations opposite to the lesion site within 20 min of the APO treatment (Cenci et al., 1998) were considered successfully lesioned and included in the study.

2.4. Elevated body swing test

The elevated body swing test (EBST) was used to estimate the effects of unilateral 6-OHDA lesions on the nigrstriatal pathway (Borlongan and Sanberg, 1995). 5 out of the 12 recorded 6-OHDA-lesioned rats were randomly selected for EBST between d2 and d11. These animals were placed consecutively into a Plexiglas box and were allowed to get habituated for 2 min. Each animal was held approximately at the base of its tail and then elevated to 2.5 cm above the surface on which it had rested. The animal was held on the vertical axis and a swing was recorded whenever the animal moved its head out of the vertical axis to either side. Before attempting another swing, the animal had to return to the vertical position for the next swing to be counted. The total number of swings made to the right side was divided by the total number of swings made to both sides to get the percentage of contralateral, right swings. The criterion for biased swing behavior was set at 70% or higher (Borlongan and Sanberg, 1995).

2.5. Induction of dyskinesia by chronic levodopa treatment

6-OHDA-treated animals were submitted to LD treatment (LD 100 mg plus benserazide 25 mg, Madopar LIQ® 125 mg dissolved onto 200 ml of drinking water). We adopted an oral schema of administration in order to permit a chronic exposure without interfering with the electrophysiological recordings of LFPs. In order to confirm if the LD induction was successfully achieved, 4 weeks later we performed a sub-cutaneous LD test on 8 rats (15 mg/kg LD plus 8 mg/kg benserazide) in order to characterize the animals showing LID. The behavioral assessment was performed by observing the animals in their individual cages, as already described (Cenci et al., 1998). Abnormal movements were scored according to a scale of 0 to 4 for each of the following four categories: 1) limb dyskinesia, 2) axial dystonia, 3) orolinguinal movements and 4) rotatory/locomotor behavior. “0” was assigned in the case of absence of abnormal movements; “1” indicated the presence of dyskinesia occurring for less than half the observational period; “2” was attributed when dykinetic movements occurred for more than half the observational period; “3” indicated a condition in
which constant dyskinesia was only briefly interrupted; and “4” refers to constant, uninterrupted dyskinesia. The behavioral assessment yielded a subdivision of chronically LD treated rats into dyskinetic and non-dyskinetic sub-groups.

2.6. Electrophysiological recordings

LFPs were simultaneously recorded from the ipsilateral GP and both frontal cortices (electroencephalogram; EEG) in awake, freely moving animals (Fig. 1B).

Electrodes for electrophysiological recordings were implanted immediately after the 6-OHDA lesion in order to start daily recordings, starting the day of lesion. Two gold 1 mm diameter screw electrodes (gold plated screws, conical cross S1, Svenska Dentorama AB) were implanted bilaterally in the frontal cortex (coordinates: 2 mm anterior of the bregma, 3 mm laterally to the midline in the left and right frontal skull (Paxinos and Franklin, 2004) under isoflurane anesthesia and after 6-OHDA injection. Also, a wire recording electrode (22 μm, Stablohm 650; California Fine Wire, Grover Beach, California) was implanted into the GP (coordinates: −1.0 mm posterior of the bregma, 3.0 mm lateral to the midline and 6.0 mm ventral to the cortical surface (Paxinos and Franklin, 2004)). One reference epidural screw electrode was placed over the right cerebellar hemisphere. All electrodes were connected to a miniature custom-built socket (360–6746 RS Components, Mörfelden-Walldorf, Germany), which was cemented to the skull with stainless-steel anchor screws (Plastics One) and paladur dental acrylic cement (Dental Pro SA, Manno, Switzerland). LFP recordings were obtained for 10 min during rest periods at the same time each day (10.00 a.m.). During the recordings, the animals were kept in a quiet condition to avoid any alerting stimuli except during the APO test where the animals had a rotatory patterned behavior.

2.7. Data acquisition and analysis of electrophysiological recordings

We performed the electrophysiological recordings every day, starting the day after the surgery (T0). The signal was digitalized on-line with a Spike2 interface and acquisition software (version 6.1; Cambridge Electronic Design Ltd., Cambridge, UK) with a sampling rate of 1 kHz. Epochs of 100 s, which were free of artifacts and representative of the overall recording, were selected from 10 min of recordings. We applied an off-line band-pass filter between 8 Hz and 100 Hz and then smoothed the epochs to 250 Hz. We calculated the total power values using a dedicated Spike2 script (SUDSA 22) in the 20–35 Hz (high β) and 60–80 Hz (γ) frequency range.

2.8. Tyrosine hydroxylase immunohistochemistry

After completing the recordings, rats were anesthetized with 3% isoflurane in oxygen and perfused intracardially with 200 ml cold saline followed by 200 ml 4% paraformaldehyde and heparine (10 U/ml) in a phosphate buffer solution. The brains were removed immediately and post-fixed in the same fixative solution overnight at 4 °C. Coronal brain 40-μm-thick sections were cut with an Oxford vibratome across the entire rostrocaudal extent of the striatum and midbrain and were
collected and stored at 4 °C in 0.1 M phosphate buffer that contained 0.02% sodiumazide. We established the degree of dopaminergic damage within the substantia nigra compacta (SNc) and the ipsilateral striatum by tyrosine hydroxylase (TH) immunostaining (Fig. 1C; Galati et al., 2010). Stained sections were also used to verify the position of the electrode within the GP. Free-floating sections were washed three times with Tris-buffered saline, pH 7.4, and endogenous peroxidase activity was inactivated by Tris-buffered saline containing 2% H2O2. The sections were rinsed with Tris-buffered saline (0.1% Triton X-100 and 2% normal goat serum) and incubated with 2% normal goat serum followed by overnight incubation at 4 °C with mouse anti-TH primary antibodies (1:1000; Immunostar Inc., Hudson, WI, USA). Primary antibodies were detected using a biotinylated secondary antibody (Vector Laboratories, Vectastain ABC Kit, Burlingame, CA, USA) and an avidin horseradish peroxidase–diaminobenzidine–H2O2 chromogen system (Sigma Fast; Sigma-Aldrich). After the diaminobenzidine reaction, sections were rinsed with Tris-buffered saline, mounted on gelatin-coated slides, dehydrated, and coverslipped with Permount for light microscope examination. The sections were observed and photographed with a light microscope (Olympus BX51, Tokyo, Japan) equipped with an automatic microcamera (Leica DC 300F, Q550 IW Soft, Wetzlar, Germany).

2.9. Image analysis for striatal fiber density measurement

After TH staining, the images of striatal sections were acquired with a camera (Sony DXC, Sony, Belgium) that was connected to the microscope and a computer. Density was measured using a specific software, the Gray Scale Program included in IAS 2000 (Delta Sistemi, Milan, Italy); this program, in principle, allows the transformation of the image density into a scale (from 0 to 255; the error bar is the SEM. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

Table 1

<table>
<thead>
<tr>
<th>Animal used in this study</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total rats included in the study</td>
<td>36</td>
</tr>
<tr>
<td>Rats treated at LBN (CH)</td>
<td>24</td>
</tr>
<tr>
<td>Rats processed for histology in Rome</td>
<td>12</td>
</tr>
<tr>
<td>EBST test</td>
<td>5</td>
</tr>
<tr>
<td>APO test</td>
<td>18</td>
</tr>
<tr>
<td>APO +</td>
<td>17</td>
</tr>
<tr>
<td>APO –</td>
<td>1</td>
</tr>
<tr>
<td>Recording data</td>
<td>18</td>
</tr>
<tr>
<td>Sham-lesioned, recorded pre- and post-apo test</td>
<td>1</td>
</tr>
<tr>
<td>6-OHDA-lesioned, recorded pre- and post-apo test</td>
<td>1</td>
</tr>
<tr>
<td>6-OHDA-lesioned, LD treated, recorded pre- and post-apo test</td>
<td>6</td>
</tr>
<tr>
<td>6-OHDA-lesioned, recorded only pre-apo test</td>
<td>5</td>
</tr>
<tr>
<td>6-OHDA-lesioned, LD treated, recorded only post-apo test</td>
<td>5</td>
</tr>
<tr>
<td>Rats observed for LD</td>
<td>8</td>
</tr>
<tr>
<td>Dyskinetic rats</td>
<td>5</td>
</tr>
<tr>
<td>Non-dyskinetic rats</td>
<td>3</td>
</tr>
<tr>
<td>Histology</td>
<td>19</td>
</tr>
<tr>
<td>Rome rats</td>
<td>12</td>
</tr>
<tr>
<td>LBN rats</td>
<td>7</td>
</tr>
</tbody>
</table>

2.10. Statistical analysis

Statistical analysis was performed using statistical software (IBM SPSS). The power of the two analyzed frequency bands were tested for normal distribution by the Kolmogorov–Smirnov test. In the first 10 days, we defined significant fluctuations as a change in power magnitude that was greater than the mean change ± 2 standard deviations (SD).

We tested the power of the frequency bands for the factor “time” in the subsequent period after the injection of 6-OHDA (T0, first 10 days, second 10 days and APO test) and during LD treatment (1 W, first week; 2 W second week; 3 W, third week; 4 W, fourth week) by repeated-ANOVA analysis (RM-ANOVA) with a Greenhouse-Geisser correction in all rats. The same analysis was chosen for the behavioral analysis. In case of significance, the post hoc test was corrected accordingly, using Bonferroni correction.

A Pearson correlation was used to correlate behavioral data (EBST test performed on the following days: d2, d3, d4, d5, d7, d8, d9, d10, d11) with the βB power.

Finally, we used a parametric t-test analysis for comparison of the total cumulative power during LD treatment between dyskinetic and non-dyskinetic animals, between the left and right TH striatal density.

3. Results

The study design is depicted in Fig. 1A, and the number of animals in Table 1.

3.1. The 6-OHDA injection caused a progressive increase of high βB, matching the development of Parkinsonism and TH-staining reduction

We simultaneously recorded the LFPs of 14 animals (6-OHDA-lesioned rats n = 13; sham-lesioned rat n = 1) from the bilateral frontal cortices and the left GP during the period encompassed by the 6-OHDA injection and the APO test. One 6-OHDA-lesioned rat produced a negative result to the APO test and was excluded from data analysis. We found a similar pattern of frequency oscillatory activity in the three different brain structures of the 6-OHDA-lesioned rats (Fig. 2). A RM-ANOVA determined that power of the high βB significantly changed during the days between the 6-OHDA lesion (T0) and the APO test (T20) in the three structures (RM-ANOVA, n = 12, frontal left: F = 9.882, P = 0.002; frontal right F = 32.703, P = 0.000; GP: F = 13.639, P = 0.012; Fig. 2).

Post hoc analysis using the Bonferroni test correction revealed that high βB increased in the first 10 days after the 6-OHDA injection in the frontal left, the frontal right, and the left GP (T0 vs 1st 10 days; P = 0.006; P = 0.007; P = 0.011 respectively; Fig. 2). The comparison of high βB power between the 1st 10 days and 2nd 10 days showed a further, unexpected increase of the high βB significance only in the frontal right cortex (1st 10 days vs 2nd 10 days; P = 0.007; Fig. 2). In the sham-lesioned rat, we did not observe any change (data not shown).

Within the first 10 days after the 6-OHDA injection, we found a significant increase of βB power on the fifth day in both the left and right cortices and on the fourth day in the GP (~2-SD).

As depicted in Fig. 2, we found no clear changes between the basal values of γB during the 20-day period after the injection of 6-OHDA.

Behavioral data analysis was performed by the EBST on five randomly selected 6-OHDA-lesioned rats 8 days after DA depletion. Later, these rats tested positive for the APO test). The EBST test showed a clear side-
A Frontal left ECoG

B Frontal right ECoG

C Pallidal LFP

D Elevated Body Swing Test
turning dominance that reached significance on the fifth day after the 6-OHDA injection (n = 5; F = 4.629, P = 0.035; d4 vs d5, P = 0.028; Fig. 2D). A Pearson correlation between electrophysiological and behavioral data, performed on 5 rats over 8 days, demonstrated a positive correlation between \( \beta \) power in the three structures and all the behavioral data collected during the first two weeks after the DA depletion (Fig. 3). In detail, we found a robust positive correlation between GP \( \beta \) power and EBST (frontal left: \( r = 0.404, n = 29, P = 0.030 \); Fig. 3A; frontal right \( r = 0.369, n = 29, P = 0.049 \); Fig. 3B; GP: \( r = 0.565, P = 0.001 \); Fig. 3C).

Furthermore, the histological evaluation demonstrated an initial damage of DA fibers: the animals sacrificed within the 1st 10 days showed a significant reduction of TH staining in the lesioned hemisphere in comparison with the contralateral ones (\( n = 10; 141.9 \pm 5.1 \) vs 158.3 \( \pm 5.7 \); \( P = 0.05 \); Fig. 4C).

This difference was most pronounced in the 2nd 10 day period (\( n = 5; 149.8 \pm 1.62 \) vs 165.6 \( \pm 3.5 \); \( P = 0.006 \); Fig. 4D), yet there was no statistical difference between the 1st 10 days and the 2nd 10 day periods. In the control and sham groups, the difference between the two hemispheres was not significant, as expected (for the lesioned side control \( n = 6; 123.8 \pm 5.4 \) vs sham \( n = 6 \) MA SONO SEZIONI DI \( N = 1 \) RAT, 136.9 \( \pm 2.5 \) in comparison with the contralateral side, control \( n = 5, 120.3 \pm 2.5 \) vs sham \( n = 6, 137.5 \pm 2.5 \), respectively, \( P < 0.05 \); Fig. 4).

3.2. APO induced a significant increase of \( \gamma B \) power selectively in the GP but not in the cortex

The APO test caused a sharp increase \( \gamma B \) power in both the left and right cortices (Fig. 2A, B); however, this failed to reach a statistical significance. Conversely, the RM-ANOVA found a significant change of the \( \gamma B \) power in the GP (\( F = 78.742, P = 0.000 \)). Specifically, the \( \gamma B \) power was augmented significantly during the APO test compared with the basal value at 10 days and 20 days after the 6-OHDA injection (T0 vs APO, \( n = 12, P = 0.002 \); 1st 10 days vs APO, \( P = 0.008 \); 2nd 10 days vs APO, \( P = 0.006 \); Fig. 2C).

3.3. The chronic LD treatment caused a progressive decline of high \( \beta \) and increase of \( \gamma B \) power

After the APO test, eleven rats were subjected to oral LD treatment for four weeks, whereas, 1 rat did not receive it (sham-LD treated). In agreement with the results of the APO test, after the start of the LD treatment, we observed a progressive reduction of the power of \( \beta \) in both the frontal cortices and the GP (\( n = 11; \) RM-ANOVA with a Greenhouse–Geisser correction for left cortex: \( F = 15.289, P = 0.005 \); right cortex: \( F = 32.339, P = 0.001 \); GP: \( F = 7.314, P = 0.019 \); Fig. 2). This reduction was slightly lower in the left frontal cortex with a substantial reduction of the high \( \beta \) power between the last week and the first three weeks (W1 vs W4, \( P = 0.003 \); W2 vs W4, \( P = 0.023 \); W3 vs W4, \( P = 0.025 \); Fig. 2A). Unexpectedly, the high \( \beta \) power decrease was most pronounced on the right, unlesioned side (W1 vs W2, \( P = 0.013 \); W1 vs W3, \( P = 0.022 \); W1 vs W4, \( P = 0.004 \); W2 vs W4, \( P = 0.008 \); Fig. 2B). A significant reduction of high \( \beta \) power was observed in the GP only between the first and the last weeks (W1 vs W4, \( P = 0.026 \); Fig. 2C).

On the contrary, the power of \( \gamma B \) progressively increased at an extensive rate in both the frontal cortices and the GP (\( n = 11; \) RM-ANOVA with a Greenhouse–Geisser correction for left cortex: \( F = 17.586, P = 0.004 \); right cortex: \( F = 26.569, P = 0.000 \); GP: \( F = 37.263, P = 0.000 \); Fig. 2). In the three structures, the augmentation of the \( \gamma B \) power reached a plateau in the third week. In detail, in the left cortex, the \( \gamma B \) increase was already significant between the first and the second weeks (W1 vs W2, \( P = 0.000 \); Fig. 2A), the second and the third weeks (W2 vs W3, \( P = 0.010 \); Fig. 2A) but not between the third and the fourth weeks (W3 vs W4, \( P = 1.000 \); \( P > 0.05 \); Fig. 2A). As far as the right, unlesioned frontal cortex is concerned, we found that the power increase reached a maximum in the second week after LD treatment (W1 vs W2, \( P = 0.000 \); W2 vs W3, \( P = 0.226 \) not significant; W3 vs W4, \( P = 1.000 \); \( P > 0.05 \); Fig. 2B). In the GP, we observed a similar dynamic pattern of \( \gamma B \) activity over the time course (W1 vs W2, \( P = 0.000 \); W2 vs W3, \( P = 0.091 \); \( P > 0.05 \); W3 vs W4, \( P = 1.000 \); \( P > 0.05 \); Fig. 2C).

3.4. The development of LID was associated with a distinctive increase of \( \gamma B \) power

Only 8 out of 11 animals completed the 4 weeks of recording during the LD treatment and were, therefore, tested with a s.c. LD challenge. Five of these animals developed LID (AlMs \( = 2.08 \pm 0.28 \)) while no involuntary movements were observed in 3 rats. Then we performed a sub-analysis between the animals that developed LID and compared them with those that did not show abnormal movement. We found a significant increase of cumulative \( \gamma B \) power in dyskinetic animals during the fourth weeks of LD treatment in all the analyzed brain structures (frontal left, \( t(6) = 4.00, P = 0.000 \); frontal right \( t(6) = 4.00, P = 0.001 \); GP\( t(6) = 4.00, P = 0.007 \); Fig. 2). On the other hand, we did not find any significant difference in the \( \beta B \) cumulative power (Fig. 2).

4. Discussion

In this study, we examined the effect of chronic DA depletion and dopaminergic treatment on the \( \beta B \) and \( \gamma B \) power within the frontal cortex and the GP using LFP recordings. Despite the lateralized feature of the rat model utilized herein, the power of \( \beta B \) and \( \gamma B \) followed a similar pattern in both frontal cortices. In line with these results, it has been demonstrated that unilateral dopaminergic denervation is able to affect the unlesioned hemisphere, which is likely due to the bilateral projections from the SNc (Vorobyov and Sengpiel, 2008; Lehmkühle et al., 2009; Morgan and Huston, 1990; Pierucci et al., 2009). In addition, a recent observation suggested the importance of inter-hemispheric coupling in the \( \beta B \) range between the left and right cortices in a rat model of PD (Javor-Duray et al., 2014). However, a cortical LFP recording from the discrete motor primary cortex demonstrated that pathological cortical oscillation in Parkinsonism could be a phenomenon, involving only the lesioned hemisphere (Halje et al., 2012).

We also observed that the high \( \beta B \) power was significantly augmented between the 1st 10 days and the 2nd 10 days only in the unlesioned, right cortex, attesting an independent mechanism underlying the emergence of electrophysiological changes at this level (Galati et al., 2008; Pierucci et al., 2009). Apart from the cortex, we focused our study on the GP for two main reasons: (i) this nucleus is not affected, at least under normal conditions, by cortical activity and (ii) it is considered a major “hub” within the BG (Galati et al., 2009; Gittis et al., 2014). Moreover, while the STN appears to be strictly locked to the cortex, the GP is subjected to a fine modulation from the striatum, STN, and SNc (Galati et al., 2009; Gittis et al., 2014). Our understanding of the GP is undergoing a reinterpretation based on recent findings; indeed, a growing body of experimental evidence demonstrates that the GP is a heterogeneous structure with different circuits (Nambu and Llinás, 1994; Hoover and Marshall, 1999; Bolam et al., 2000; Kita and Kita, 2001; Flandin et al., 2010; Nóbrega-Pereira et al., 2010; Benhamou et al., 2012; Mastro et al., 2014). Pallidal neurons fire tonically with a frequency range of 10 to 80 Hz in physiological conditions at rest in vivo, while during movement, they respond with complex temporal patterns and low correlation (DeLong et al., 1985; Jaeger et al., 1995; Nini et al., 1995; Turner and Anderson, 1997). Physiological pallidal activity is not linked to the cortex, and GP neurons usually have a high and regular firing rate that remains high during slow-wave activity (Galati et al., 2009). Recently, a novel, molecularly-defined cell type in the GP, the arpykallidal GP neuron, has been described with a lower and very irregular firing rate that is further suppressed during sleep (Mallet et al., 2012; Gittis et al., 2014). Future studies are required to clarify to what extent the robust and
chronically-developing changes in $\beta$ and $\gamma$ underlie the specific involvement of these different GP neuronal sub-types.

The main findings of the present work are threefold: (i) the change of the high $\beta$ parallels the emergence of Parkinsonian signs and was strictly and temporally associated with the severity of the reduction of TH staining; (ii) dopaminergic treatment (AP0 and LD) influenced the power of the two examined bands in contrasting ways, confirming their crucial role in BG pathophysiology; and (iii) dyskinetic animals showed a distinctive increase in $\gamma$B power compared with non-dyskinetic animals.

The link between $\beta$B and the development of Parkinsonism is based on the increased expression of this band within the BG of Parkinsonian animal models and PD patients, during surgery as well as during dopaminergic treatment and deep brain stimulation [jenkinson and Brown, 2011; Kühn et al., 2006a, 2006b, 2009a, 2009b; Devos and Defebvre, 2006]. We observed that high $\beta$ matches the emergence of Parkinsonian signs detected by a non-pharmacological test; specifically, the power of high $\beta$ had already significantly increased from the base line in the first 10 days after 6-OHDA lesioning, while there was also a right-biased swing in the EBST. Moreover, we found a positive correlation between the power of $\beta$B in the three explored structures (mainly in the GP) and the EBST. Our results seem to contradict a previous work that developed in dyskinetic rodents may be the network counterpart of dystonia (Chen et al., 2006). The more recent literature on the activity of $\gamma$B in dyskinetic PD patients (Alonso-Frech et al., 2006; Fogelson et al., 2005), similar results were observed in another hyperkinetic condition, dystonia [Chen et al., 2006]. The more recent literature on the activity of $\gamma$B in dyskinetic PD patients [Alonso-Frech et al., 2006; Fogelson et al., 2005; Silberstein et al., 2005] shows an exaggerated negative correlation between $\beta$B and $\gamma$B in dyskinetic PD patients (Alonso-Frech et al., 2006; Fogelson et al., 2005; Silberstein et al., 2005). Similar results were observed in another hyperkinetic condition, dystonia (Chen et al., 2006).

A detailed time course of the TH immunostaining in the rat striatum following 6-OHDA injection into the MFB demonstrated that 6-OHDA induced a loss of striatal innervation that became evident 3 days after the lesion and progressively decreased thereafter [Walsh et al., 2011]. This study shows even earlier changes than those observed here; however, they used a larger amount of 6-OHDA (i.e., 12 $\mu$g versus 8 $\mu$g). In agreement with the similar time lag between electrophysiological and histological data, we already evidenced right-biased behavior on the fifth day after the lesion.

Although there is a great deal of interest in the pathophysiological functioning of the BG in PD and the $\beta$B, in recent years, increasing evidence has demonstrated that the $\gamma$B can have as much impact as $\beta$B. Herein, we focused on the $\gamma$B comprised between 60 and 80 Hz since it is commonly centered on 70 Hz in recordings of the thalamus and the GP [Kempf et al., 2009]. We found that dopaminergic treatment accounted for a reduction of $\gamma$B and an increase of $\beta$B. Several studies have demonstrated a suppression of $\beta$B by dopaminergic treatment that paralleled clinical amelioration in PD patients and the reduction of $\gamma$B correlates with the degree of amelioration of the symptomology [Priori et al., 2004; Doyle et al., 2005; Kühn et al., 2006a, 2006b, 2009a, 2009b]. In a recent paper by Sharott et al. (2014), a positive correlation between the percentage of STN neurons expressing $\beta$B oscillation and the axial and rigidity signs was found; paradoxically, it was not found with bradykinesia although it is considered the main Parkinsonian feature. In contrast, in the same study, the authors demonstrated a negative correlation between $\gamma$B and bradykinesia (Sharott et al., 2014). In agreement with several human studies that found an increase of $\gamma$B after dopaminergic treatment [Alegre et al., 2005; Alonso-Frech et al., 2006; Androulidakis et al., 2007; Brown et al., 2001; Cassidy et al., 2002; Devos et al., 2006; Fogelson et al., 2005], we observed that LD treatment caused an augmentation of $\gamma$B. Our findings are in agreement with some reports in humans, showing an exaggerated negative correlation between $\beta$B and $\gamma$B in dyskinetic PD patients (Alonso-Frech et al., 2006; Fogelson et al., 2005; Silberstein et al., 2005).

One of the extreme challenges in the treatment of advanced PD patients is the difficulty in producing a stable ON-state without generating disabling LIDs. As a counterpart, studies founded on rodent models rarely define, in an unequivocal manner, the fine discrimination amongst the electrophysiological parameters that define the prokinetic ON-state versus ON-state complicated by LIDs in the same animal. Therefore, a critical point is that re-modulating the $\beta$B or $\gamma$B power distribution might produce a "therapeutic" state but also a LID state. There-
Nevertheless, it will be worth examining whether the increased γB, which was detected here, is also detectable inside the striatum. Hernandez et al. (2013), detailed that LD may normalize the perturbed spectrum of all band dynamics minus the low-γ (48 Hz), linked by spike-field coupling to fast-spiking striatal interneurons. The latter might undergo “structural changes after DA depletion” (Hernandez et al., 2013), possibly interplaying with the GP firing mode.

In conclusion, the temporal dynamic between the emergence of βB, Parkinsonian signs, and the reduction of TH staining attests to a strong association amongst these factors. The opposing behaviors of βB and γB in the same recordings bear testimony to the impact of rest and movement in our observations. Our results support an intimate role for these two bands not only during a critical stage in the pathophysiology of PD, such as the development of the Parkinsonian syndrome, but more importantly, during the development of LID.

Acknowledgments

We thank Fondazione per lo studio delle malattie neurodegenerative delle persone adulte e dell’anziano for financial support to CS and SG. We thank Chiara Prosperetti for a critical reading of the manuscript. The authors are particularly grateful to Camille Mittendorf for the English revision of the manuscript.

Fig. 4. Immunocytochemical results in sham, control and 6-OHDA-lesioned animals (at 10 and 20 days following 6-OHDA). Shown are exemplary photomicrographs and, on the right, cumulative histograms for optical density assessment through gray scaling (§), inversely correlated to bright light. (A) Right and left striata of a control (ctr) rat. The box plot represents the mean of the gray density (each is the mean of 5 coronal serial sections, N = 3 rats). No significant difference amongst right and left striatum. (B) Right and left striata of a sham rat; the box plot represents the optical density evaluation (mean of 5 coronal serial sections, n = 1 animal). No significant difference amongst the two sites. (C) Exemplary right (contralateral) and left (ipsilateral to the lesion) striatum of a rat sacrificed ten days after the 6-OHDA injection; the box plot on the right (5 coronal serial sections in each animal, N = 10 animals) illustrates the optical gray density percentage, in unlesioned and lesioned rats, respectively 141.9 ± 5.1 vs 158.3 ± 5.7. This difference was significant (one way ANOVA followed by Bonferroni correction for multiple comparisons, P < 0.05). (D) Right (contralateral) and left (ipsilateral to the lesion) striatum of a rat sacrificed twenty days after the 6-OHDA injection; the right box plot (mean of 5 coronal serial sections in each animal, N = 5 animals) illustrates the optical gray density percentage, respectively 149.8 ± 1.62 vs 165.6 ± 3.5; P < 0.01 (one way ANOVA followed by Bonferroni correction for multiple comparisons, P < 0.01). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
References


